Raphael Rifkin-Zybutz and Sameer Jauhar summarise the recently published ANTLER trial, which explores whether antidepressant maintenance can reduce the risk of relapse in depression.
[read the full story...]
Douglas Badenoch explores a meta-analysis of follow-up data from clinical trials of antidepressants, which found a small but significant increase in suicide risk.
[read the full story...]
Rina Dutta and Patrick McLaughlin summarise a new study looking at the effects of SSRIs (Selective Serotonin Reuptake Inhibitors) on rating-scale-assessed suicidality in adults with depression.
This study published in the British Journal of Psychiatry supports the conclusion that SSRIs remain a safe and effective treatment in depression for those aged 18 and over.
[read the full story...]
Carmine Pariante is positive about a recent systematic review and meta-analysis of antidepressants for the treatment of depression in schizophrenia.
[read the full story...]
Andrew Shepherd considers the implications of a recent network meta-analysis of the efficacy and tolerability of antidepressants for children and adolescents with depression.
[read the full story...]
Alex Langford explores the emerging findings from a recent meta-analysis looking at the efficacy and safety of antidepressants added to antipsychotics for people with schizophrenia and schizophrenia-like psychosis.
[read the full story...]
Marcus Munafo explores a recent study that uses a machine learning approach across two trials (STARD*D and CO-MED) to try and predict treatment outcomes (primarily focusing on the antidepressant citalopram) for depression.
[read the full story...]
Lisa Burscheidt summarises a recent randomised controlled trial of combined methylphenidate and citalopram for depression in older people, which presents promising but limited findings.
[read the full story...]
In addition to its impact on quality of life, panic disorder can have a number of costly consequences such as lost productivity – particularly if also associated with agoraphobia. Cost-effectiveness is therefore an important consideration in choosing the optimal treatment for panic disorder, which might improve value via the cost side of the equation. A recent [read the full story…]
